This company is no longer active
Diffusion Pharmaceuticals Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Información clave
-19.2%
Tasa de crecimiento de los beneficios
48.6%
Tasa de crecimiento del BPA
| Crecimiento de la industria Biotechs | -14.6% |
| Tasa de crecimiento de los ingresos | n/a |
| Rentabilidad financiera | -62.3% |
| Margen neto | n/a |
| Última actualización de beneficios | 30 Sep 2022 |
Actualizaciones de resultados anteriores recientes
No hay actualizaciones
Recent updates
Desglose de ingresos y gastos
Cómo gana y gasta dinero Diffusion Pharmaceuticals. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 30 Sep 22 | 0 | -15 | 8 | 7 |
| 30 Jun 22 | 0 | -24 | 8 | 8 |
| 31 Mar 22 | 0 | -24 | 8 | 8 |
| 31 Dec 21 | 0 | -24 | 7 | 8 |
| 30 Sep 21 | 0 | -25 | 7 | 10 |
| 30 Jun 21 | 0 | -17 | 7 | 11 |
| 31 Mar 21 | 0 | -18 | 7 | 11 |
| 31 Dec 20 | 0 | -16 | 6 | 9 |
| 30 Sep 20 | 0 | -16 | 6 | 9 |
| 30 Jun 20 | 0 | -14 | 5 | 7 |
| 31 Mar 20 | 0 | -12 | 5 | 6 |
| 31 Dec 19 | 0 | -12 | 5 | 7 |
| 30 Sep 19 | 0 | -14 | 5 | 6 |
| 30 Jun 19 | 0 | -18 | 5 | 6 |
| 31 Mar 19 | 0 | -18 | 6 | 6 |
| 31 Dec 18 | 0 | -27 | 6 | 6 |
| 30 Sep 18 | 0 | -20 | 6 | 6 |
| 30 Jun 18 | 0 | -10 | 6 | 6 |
| 31 Mar 18 | 0 | 4 | 6 | 6 |
| 31 Dec 17 | 0 | -3 | 6 | 5 |
| 30 Sep 17 | 0 | -7 | 6 | 5 |
| 30 Jun 17 | 0 | -15 | 8 | 5 |
| 31 Mar 17 | 0 | -30 | 6 | 5 |
| 31 Dec 16 | 0 | -18 | 9 | 6 |
| 30 Sep 16 | 0 | -18 | 9 | 6 |
| 30 Jun 16 | 0 | -14 | 5 | 6 |
Ingresos de calidad: DP81 is currently unprofitable.
Margen de beneficios creciente: DP81 is currently unprofitable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: DP81 is unprofitable, and losses have increased over the past 5 years at a rate of 19.2% per year.
Acelerando crecimiento: Unable to compare DP81's earnings growth over the past year to its 5-year average as it is currently unprofitable
Beneficios vs. Industria: DP81 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-15.9%).
Rentabilidad financiera
Alta ROE: DP81 has a negative Return on Equity (-62.32%), as it is currently unprofitable.